Comparing the effect of depo-medroxyprogesterone acetate (DMPA) and bromocriptine in women with symptomatic myoma uteri: a randomized controlled trial

Phase 4

• Conditions: Symptomatic myoma uteri; Myoma uteri

• Registration Number: TCTR20200714001
• Lead Sponsor: none

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-07-14
• Study Completion: 2021-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: Female
• Target Recruitment: 126

Inclusion Criteria

1.Woman ages between 20-50 years old.
2.Myoma uteri confirmed by transvaginal ultrasound
3.Pelvic pain or abnormal uterine bleeding
4.Waiting for surgery or premenopausal woman
5.Woman who can reading and writing

Exclusion Criteria

1.Heavy uterine bleeding that must have emergency treatment
2.Transvaginal ultrasound found other disease in pelvic organ such as ovarian cancer
3.Woman who take COC in 1 month or DMPA/implant in 3 months ago
4.Deny to taked transvaginal ultrasound
5.Pregnancy, lactation or fertility desires
6.Abnormal liver or kidney function
7.Ergot allergy
8.Bleeding disorder
9.Contraindication to bromocriptine including allergy, uncontrolled hypertension, pregnancy induced hypertension, myocardial infarction and severe psychological diseases.
10.Contraindication to DMPA including uncontrolled hypertension, severe cirrhosis or liver tumor, Kidney or vascular complication from DM , venous thrombosis, cerebrovascular or myocardial infarction, breast cancer and undiagnosed abnormal uterine bleeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified